Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report.
Transl Pediatr
December 2024
Department of Infectious Diseases, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease in which the Epstein-Barr virus (EBV) persists and replicates, causing chronic symptoms and fatal complications. The treatment of CAEBV is still evolving. Our case report showed a new therapy for CAEBV.
View Article and Find Full Text PDFHyaluronic Acid-Based pH-Sensitive Nanogel: Synthesis, Characterization, and Assessment for Acyclovir Delivery In Vitro and In Vivo.
Biomacromolecules
January 2025
Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt.
Acyclovir (ACV) is a potentially effective antiviral medication; however, it has a serious drawback, which is its poor solubility, bioavailability, and short half-life. The goal of this study is to improve its drawbacks through the synthesis of nanogels. In this study, the cross-linked hyaluronic acid-grafted poly(acrylamide--itaconic acid) nanogel is synthesized successfully through free radical polymerization and used as a safe pH-responsive carrier for ACV.
View Article and Find Full Text PDFDifferences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database.
Expert Opin Drug Saf
October 2024
Department of Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- The study compared the safety profiles of four anti-herpesvirus drugs—acyclovir, ganciclovir, valaciclovir, and foscarnet—using data from the FDA Adverse Event Reporting System from 2004 to 2023.
- All drugs showed significant risks for hematotoxicity, with ganciclovir and foscarnet being the most myelosuppressive.
- Specific associations were noted: foscarnet posed the highest risk for renal impairment and seizures, while acyclovir had strong ties to neurotoxicity and severe skin reactions.
A drug repurposing screen identifies decitabine as an HSV-1 antiviral.
Microbiol Spectr
November 2024
The Department of Molecular Biology and Biochemistry, The University of California Irvine, Irvine, California, USA.
Unlabelled: Herpes simplex virus type 1 (HSV-1) is a highly prevalent human pathogen that causes a range of clinical manifestations, including oral and genital herpes, keratitis, encephalitis, and disseminated neonatal disease. Despite its significant health and economic burden, there is currently only a handful of approved antiviral drugs to treat HSV-1 infection. Acyclovir and its analogs are the first-line treatment, but resistance often arises during prolonged treatment periods, such as in immunocompromised patients.
View Article and Find Full Text PDFAn exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs.
J Dermatol
October 2024
Medical Affairs, Maruho Co., Ltd, Osaka, Japan.
Amenamevir is an oral once-daily antiherpesvirus drug that can be administered without dose adjustment in patients with impaired renal function. There are currently no clinical data on immunocompromised patients with herpes zoster treated with amenamevir. Therefore, an exploratory study of the efficacy and safety of amenamevir against herpes zoster in patients with immunosuppression was conducted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!